Skip to main content
Top
Published in: Rheumatology International 11/2009

01-09-2009 | Original Paper

Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis

Authors: Xinwei Wang, Zhiming Lin, Qiujing Wei, Yingjuan Jiang, Jieruo Gu

Published in: Rheumatology International | Issue 11/2009

Login to get access

Abstract

The objective of this study was to investigate the expression of IL-23 and IL-17 and the influence of IL-23 on IL-17 production in ankylosing spondylitis (AS) patients. IL-23 and IL-17 levels in the serum and supernatants of cultured peripheral blood mononuclear cells (PBMCs) were determined by ELISA. IL-23p19 mRNA expression in PBMCs were analyzed using RT-PCR. The patients with AS at active stage showed elevated levels of IL-23 and IL-17 in the serum and supernatants of cultured PBMCs. A higher expression of IL-23p19 mRNA in PBMCs of AS patients was also observed. A significantly enhanced production of IL-17 in the supernatants of cultured PBMCs was found in the presence of recombinant IL-23 and this effect was more significant in patients with AS. The results suggest that IL-23 and IL-17 may play critical roles in the pathogenesis of AS and IL-23-stimulated production of IL-17 by PBMCs may be responsible for the development of AS.
Literature
3.
go back to reference Pirhonen J, Matikainen S, Julkunen I (2002) Regulation of virus-induced IL-12 and IL-23 expression in human macrophages. J Immunol 169:5673–5678PubMed Pirhonen J, Matikainen S, Julkunen I (2002) Regulation of virus-induced IL-12 and IL-23 expression in human macrophages. J Immunol 169:5673–5678PubMed
4.
6.
9.
go back to reference Kotake S, Udagawa N, Takahashi N et al (1999) IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103:1345–1352. doi:10.1172/JCI5703 PubMedCrossRef Kotake S, Udagawa N, Takahashi N et al (1999) IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103:1345–1352. doi:10.​1172/​JCI5703 PubMedCrossRef
18.
go back to reference Chen Y, Langrish CL, McKenzie BS et al (2006) Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest 116:1317–1326. doi:10.1172/JCI25308 PubMedCrossRef Chen Y, Langrish CL, McKenzie BS et al (2006) Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest 116:1317–1326. doi:10.​1172/​JCI25308 PubMedCrossRef
19.
go back to reference Nakae S, Nambu A, Sudo K, Iwakura Y (2003) Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 171:6173–6177PubMed Nakae S, Nambu A, Sudo K, Iwakura Y (2003) Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 171:6173–6177PubMed
20.
go back to reference Lubberts E, Koenders MI, Oppers-Walgreen B et al (2004) Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 50:650–659. doi:10.1002/art.20001 PubMedCrossRef Lubberts E, Koenders MI, Oppers-Walgreen B et al (2004) Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 50:650–659. doi:10.​1002/​art.​20001 PubMedCrossRef
22.
27.
go back to reference Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL (2003) Interleukin-23 promotes a distinct CD4 T-cell activation state characterized by the production of interleukin-17. J Biol Chem 278:1910–1914. doi:10.1074/jbc.M207577200 PubMedCrossRef Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL (2003) Interleukin-23 promotes a distinct CD4 T-cell activation state characterized by the production of interleukin-17. J Biol Chem 278:1910–1914. doi:10.​1074/​jbc.​M207577200 PubMedCrossRef
Metadata
Title
Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis
Authors
Xinwei Wang
Zhiming Lin
Qiujing Wei
Yingjuan Jiang
Jieruo Gu
Publication date
01-09-2009
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 11/2009
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-0883-x

Other articles of this Issue 11/2009

Rheumatology International 11/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.